Corsair Gaming Inc vs Quest Diagnostics Inc — how do they compare? Corsair Gaming Inc trades at $13.63 (market cap $1.42B), while Quest Diagnostics Inc trades at $230.97 (market cap $25.48B). The key difference: Quest Diagnostics Inc is far larger — about 17.9× Corsair Gaming Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Corsair Gaming Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and Quest Diagnostics Inc for 56 Days on average.
| CRSR | DGX | |
|---|---|---|
Market Cap | $1.42B | $25.48B |
Volume | 1,160,938 | 941,866 |
Sector | Technology | Health |
52-Week High | $14.35 | $247.45 |
52-Week Low | $4.58 | $173.49 |
Typical Hold Time | 25 Days | 56 Days |
Enterprise Value | $1.41B | $31.23B |
Dividend Yield | — | 1.49% |
Signals from Pluang's Aura AI — not financial advice
Corsair Gaming (CRSR) trades at $13.63, up 0.29% with a bullish technical signal. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.23 exceeding expectations by 228%. Recent product launches like the VOXARA microphone and strategic acquisitions demonstrate growth initiatives. Financials show improving cash flow trends with projected 2026 operating cash flow of $106 million, though net income margins remain thin at 2.53%.
CRSR presents a mixed outlook with strong earnings momentum and product innovation offset by valuation concerns at 42x P/E. Analyst consensus is cautious with 64% hold ratings and $12.40 price target below current levels. Key risks include competitive gaming peripherals market and execution of growth strategy. The stock's near-term direction hinges on Q3 earnings delivery and sustained margin improvement.
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →